Aptinyx's lead drug makes cut in small fibromyalgia trial, setting the stage for larger chronic pain study
Four months ago, its lead drug fell short of hitting statistical significance in a diabetic peripheral neuropathy (DPN) study. On Monday, the newly-public Aptinyx …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
